secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001193125-25-320150
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma buys 1.5% royalty on Nuvalent's pipeline for up to $315M
-----------------------------------------------------------------------

- Royalty Pharma acquired a preexisting 1.5% net-sales royalty on neladalkib and zidesamtinib from an undisclosed third party.
- The deal value is up to $315 million; Nuvalent is not a party to the transaction.
- Nuvalent clarifies the 'low single digit preexisting royalty' is exactly 1.5% of net sales of both candidates.
- Nuvalent's revenue share agreement with its scientific founder remains unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312525320150/0001193125-25-320150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312525320150/d53736d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-320150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer